Word: genentech
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...core research areas, scientists are mining new sources for inspiration, be it China or genetic engineering. At the same time, Roche's bosses, from their base in Basel, continue to lead the pack in acquiring expertise, a talent recently seen in the company's bid to control biotech superstar Genentech. Together, the two strategies form the nucleus of how Roche plans to deliver best-in-class products--faster, more cheaply and more reliably--to market. "The days of an attrition-based pipeline are over," says Lee Babiss, head of global pharma research. "We've responded by making R&D much...
When the Alnylam deal was announced in July 2007, Schwan quipped that it could become Roche's "second Genentech." In his wildest dreams. With a market cap of $95 billion, Genentech--of which Roche has owned a 55% majority stake since 1990--has produced some of the most cutting-edge best sellers on the pharmaceutical market today. Its pipeline remains one of the industry's most promising. In the past, Roche always applied a light touch to this golden goose, but this summer it became too tempting for Schwan. On July 21, in what will probably amount to a hostile...
Brent A. Appleton, a Ph.D. student who graduated in 2004, took a position at Genentech, a biotechnology company based in San Francisco...
...outcome," says Dr. John Sorenson, an AMD expert in New York City. "You can already hear the lawyers say, 'Doctor, why didn't you use the approved drug?' So we'll use the approved drug." Avastin has not been subjected to rigorous testing for AMD, and it would take Genentech years and huge expense to do those tests with Avastin - only to compete with the company's new drug...
...Genentech assures the public that patients will not be priced out of the vision-saving medication. "We've got a comprehensive program in place so cost is not a barrier to using Lucentis," says Megan Pace, spokeswoman for the company. But while poorer patients may receive aid, the price will still wallop those institutions that bear the brunt of health-care costs: insurance companies, Medicare, and Medicaid. For them, too, Genentech might be onto something bigger than they bargained...